JP2024056938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024056938A5 JP2024056938A5 JP2024022697A JP2024022697A JP2024056938A5 JP 2024056938 A5 JP2024056938 A5 JP 2024056938A5 JP 2024022697 A JP2024022697 A JP 2024022697A JP 2024022697 A JP2024022697 A JP 2024022697A JP 2024056938 A5 JP2024056938 A5 JP 2024056938A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- polynucleotide
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 239000002157 polynucleotide Substances 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000050320 human TNFRSF4 Human genes 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018088101 | 2018-05-23 | ||
| CNPCT/CN2018/088101 | 2018-05-23 | ||
| PCT/CN2019/088013 WO2019223733A1 (en) | 2018-05-23 | 2019-05-22 | Anti-ox40 antibodies and methods of use |
| JP2020565492A JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ｏｘ４０抗体及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Division JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ｏｘ４０抗体及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024056938A JP2024056938A (ja) | 2024-04-23 |
| JP2024056938A5 true JP2024056938A5 (https=) | 2024-10-17 |
Family
ID=68615676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Active JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ｏｘ４０抗体及び使用方法 |
| JP2024022697A Withdrawn JP2024056938A (ja) | 2018-05-23 | 2024-02-19 | 抗ｏｘ４０抗体及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Active JP7489922B2 (ja) | 2018-05-23 | 2019-05-22 | 抗ｏｘ４０抗体及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12103974B2 (https=) |
| EP (1) | EP3797123A4 (https=) |
| JP (2) | JP7489922B2 (https=) |
| KR (1) | KR20210013708A (https=) |
| CN (1) | CN112566935B (https=) |
| AU (1) | AU2019272384A1 (https=) |
| BR (1) | BR112020023746A2 (https=) |
| EA (1) | EA202092460A1 (https=) |
| IL (1) | IL278772A (https=) |
| MX (2) | MX2020012567A (https=) |
| SG (1) | SG11202011024WA (https=) |
| TW (1) | TW202016133A (https=) |
| WO (1) | WO2019223733A1 (https=) |
| ZA (1) | ZA202006931B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| US20230002500A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| JP2023503399A (ja) * | 2019-11-21 | 2023-01-30 | ベイジーン リミテッド | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
| EP4061421A4 (en) * | 2019-11-21 | 2024-05-15 | BeiGene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| US20230011916A1 (en) * | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| BR112022009147A2 (pt) * | 2019-11-21 | 2022-07-26 | Beigene Ltd | Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune |
| JP2023503031A (ja) * | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| PE20230255A1 (es) | 2020-04-17 | 2023-02-07 | Hutchison Medipharma Ltd | Anticuerpo anti-ox40 y usos del mismo |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| KR20240122784A (ko) | 2021-12-17 | 2024-08-13 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체 및 사용 방법 |
| KR20240116755A (ko) | 2021-12-17 | 2024-07-30 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법 |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CN120476146A (zh) * | 2022-12-30 | 2025-08-12 | 甘李药业股份有限公司 | 抗ox40抗体及其应用 |
| WO2024184810A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
| WO2024184812A1 (en) | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 antibodies and methods of use |
| TW202436345A (zh) | 2023-03-06 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | 抗ｃｄ３多特異性抗體及使用方法 |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024240247A1 (en) * | 2023-05-25 | 2024-11-28 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| EP2097447A4 (en) | 2006-11-15 | 2010-12-29 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| HUE036157T2 (hu) * | 2010-03-30 | 2018-06-28 | Janssen Biotech Inc | Humanizált IL-25 ellenanyagok |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| CA2809089C (en) * | 2010-08-23 | 2018-12-18 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| CN102010407A (zh) | 2010-11-16 | 2011-04-13 | 上海科胜药物研发有限公司 | 一种合成达沙替尼的新方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG10201708048XA (en) | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| KR20250005465A (ko) * | 2015-03-03 | 2025-01-09 | 키맵 리미티드 | 항체, 용도 및 방법 |
| PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| JP2018521019A (ja) | 2015-06-08 | 2018-08-02 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体を使用して癌を治療する方法 |
| WO2017063162A1 (zh) * | 2015-10-15 | 2017-04-20 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| US10781260B2 (en) * | 2016-08-08 | 2020-09-22 | Sorrento Therapeutics, Inc. | Anti-OX40 binding proteins |
| US11203637B2 (en) | 2016-08-26 | 2021-12-21 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| EP3713958A4 (en) | 2017-11-24 | 2021-11-03 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| CN111393529B (zh) | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| TWI831778B (zh) | 2018-05-11 | 2024-02-11 | 澳門商同潤澳門一人有限公司 | 抗ox40的全人抗體及其製備方法和用途 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| US20230011916A1 (en) | 2019-11-21 | 2023-01-12 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| EP4061421A4 (en) | 2019-11-21 | 2024-05-15 | BeiGene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| BR112022009147A2 (pt) | 2019-11-21 | 2022-07-26 | Beigene Ltd | Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune |
| US20230002500A1 (en) | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| JP2023503031A (ja) | 2019-11-21 | 2023-01-26 | ベイジーン（ベイジン）カンパニー リミテッド | 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法 |
| JP2023503399A (ja) | 2019-11-21 | 2023-01-30 | ベイジーン リミテッド | 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法 |
-
2019
- 2019-05-22 BR BR112020023746-9A patent/BR112020023746A2/pt active Search and Examination
- 2019-05-22 MX MX2020012567A patent/MX2020012567A/es unknown
- 2019-05-22 AU AU2019272384A patent/AU2019272384A1/en not_active Abandoned
- 2019-05-22 US US17/055,267 patent/US12103974B2/en active Active
- 2019-05-22 CN CN201980034638.8A patent/CN112566935B/zh active Active
- 2019-05-22 EP EP19806419.8A patent/EP3797123A4/en active Pending
- 2019-05-22 SG SG11202011024WA patent/SG11202011024WA/en unknown
- 2019-05-22 JP JP2020565492A patent/JP7489922B2/ja active Active
- 2019-05-22 KR KR1020207035920A patent/KR20210013708A/ko active Pending
- 2019-05-22 WO PCT/CN2019/088013 patent/WO2019223733A1/en not_active Ceased
- 2019-05-22 EA EA202092460A patent/EA202092460A1/ru unknown
- 2019-05-23 TW TW108117808A patent/TW202016133A/zh unknown
-
2020
- 2020-11-06 ZA ZA2020/06931A patent/ZA202006931B/en unknown
- 2020-11-17 IL IL278772A patent/IL278772A/en unknown
- 2020-11-23 MX MX2024013960A patent/MX2024013960A/es unknown
-
2024
- 2024-02-19 JP JP2024022697A patent/JP2024056938A/ja not_active Withdrawn
- 2024-08-28 US US18/818,381 patent/US20240409655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024056938A5 (https=) | ||
| JP2021524256A5 (https=) | ||
| JP7241207B2 (ja) | Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子 | |
| US20160159912A1 (en) | Combination therapy of anti-her3 antibodies | |
| US11939381B2 (en) | Bispecific antibodies targeting immune checkpoints | |
| CN105968206A (zh) | 抗erbb3抗体 | |
| JP2020522280A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| JP2023532248A5 (https=) | ||
| TW202413426A (zh) | 抗ｃｃｒ８抗體及使用方法 | |
| JP2024522075A5 (https=) | ||
| JP2024519078A5 (https=) | ||
| JP2021528439A5 (https=) | ||
| EP4180457A1 (en) | Anti-cldn-18.2 antibody and use thereof | |
| US20250171556A1 (en) | Multispecific antibodies for treating cd47-associated diseases | |
| CN114269780B (zh) | 一种新型抗pd-l1抗体及其用途 | |
| AU2016203429B2 (en) | Binding Molecules to the Human OX40 Receptor | |
| HK40043144A (en) | Bispecific antibodies targeting immune checkpoints | |
| HK40114941A (zh) | 用於治疗cd47相关疾病的多特异性抗体 | |
| RU2025121328A (ru) | МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ TGFβ1, МОЛЕКУЛА, СВЯЗЫВАЮЩАЯ GARP-TGFβ1, И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| RU2025101095A (ru) | Способы лечения рака с помощью антител против tigit | |
| NZ761838B2 (en) | Cd38 antibody | |
| NZ760342B2 (en) | Cd38 modulating antibody | |
| NZ761020B2 (en) | Cd38 modulating antibody | |
| NZ761838A (en) | Cd38 antibody |